Slew Of Challenges Calls For Revised Biopharma Playbook
While not immune to the impact of a storm of macroeconomic pressures, pharma companies have pulled through before, and they’ll do it again. However, this time around, the economic, geopolitical and internal cost and revenue pressures are unique and weathering the near-term turbulence will call for smart investment strategies that not only focus on quality assets, but that update companies to take advantage of new digital opportunities.
You may also be interested in...
The worst of COVID-19’s disruption appears to be in the pharma supply chain’s rearview mirror, but logistics stakeholders still have a number of questions to answer and challenges to overcome as they attempt to become future-proof.
Despite concerns about the impact of the Inflation Reduction Act and constraining factors like inflation, EY believes more than $1.4tn in life sciences industry “firepower” should result in increased deal-making this year.
Takeda’s R&D chief Andy Plump said his company has seen data indicating game-changing characteristics for TAK-279 in psoriasis. It plans to bring the candidate into Phase III next year.